IL117594A - b - אינטורפרון ממקור בן-אדם שעבר גליקוזילציה ווקטור הכולל רצף מקודד של b - אינטורפרון ממקור בן-אדם - Google Patents

b - אינטורפרון ממקור בן-אדם שעבר גליקוזילציה ווקטור הכולל רצף מקודד של b - אינטורפרון ממקור בן-אדם

Info

Publication number
IL117594A
IL117594A IL11759496A IL11759496A IL117594A IL 117594 A IL117594 A IL 117594A IL 11759496 A IL11759496 A IL 11759496A IL 11759496 A IL11759496 A IL 11759496A IL 117594 A IL117594 A IL 117594A
Authority
IL
Israel
Prior art keywords
cells
interferon
human
vector
promoter
Prior art date
Application number
IL11759496A
Other languages
English (en)
Other versions
IL117594A0 (en
Original Assignee
Inst Of Molecul & Cell Biology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Of Molecul & Cell Biology filed Critical Inst Of Molecul & Cell Biology
Publication of IL117594A0 publication Critical patent/IL117594A0/xx
Publication of IL117594A publication Critical patent/IL117594A/he

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/565—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/505—Erythropoietin [EPO]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/108—Plasmid DNA episomal vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/15—Vector systems having a special element relevant for transcription chimeric enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/60—Vector systems having a special element relevant for transcription from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
    • C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL11759496A 1995-03-24 1996-03-21 b - אינטורפרון ממקור בן-אדם שעבר גליקוזילציה ווקטור הכולל רצף מקודד של b - אינטורפרון ממקור בן-אדם IL117594A (he)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9506051.3A GB9506051D0 (en) 1995-03-24 1995-03-24 Gene expression

Publications (2)

Publication Number Publication Date
IL117594A0 IL117594A0 (en) 1996-07-23
IL117594A true IL117594A (he) 2002-11-10

Family

ID=10771834

Family Applications (1)

Application Number Title Priority Date Filing Date
IL11759496A IL117594A (he) 1995-03-24 1996-03-21 b - אינטורפרון ממקור בן-אדם שעבר גליקוזילציה ווקטור הכולל רצף מקודד של b - אינטורפרון ממקור בן-אדם

Country Status (16)

Country Link
US (1) US6207146B1 (he)
EP (1) EP0815251A1 (he)
JP (1) JPH11502705A (he)
KR (1) KR19980703275A (he)
CN (1) CN1185180A (he)
AP (1) AP730A (he)
AU (1) AU722341B2 (he)
BR (1) BR9607831A (he)
CA (1) CA2216174A1 (he)
GB (2) GB9506051D0 (he)
HK (1) HK1005248A1 (he)
HU (1) HUP9800520A3 (he)
IL (1) IL117594A (he)
NO (1) NO974367L (he)
NZ (1) NZ303133A (he)
WO (1) WO1996030531A1 (he)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002310922A1 (en) * 2001-05-04 2002-11-18 Institute Of Molecular And Cell Biology Interferons in the treatment of ischemia
FR2843973B1 (fr) * 2002-08-30 2006-07-07 Agronomique Inst Nat Rech Cassettes d'expression procaryotes regulees par le zinc
GB0524782D0 (en) * 2005-12-05 2006-01-11 Chiron Srl Analysis of samples
CN100432230C (zh) * 2006-05-11 2008-11-12 南京大学 一种金属硫蛋白融合表达方法及其应用
EP2205752B1 (en) * 2007-10-25 2016-08-10 Sangamo BioSciences, Inc. Methods and compositions for targeted integration
LT3768846T (lt) * 2018-03-21 2023-08-10 Aldevron, L.L.C. Virusiniai ir nevirusiniai nanoplazmidiniai vektoriai su patobulinta gamyba

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5514567A (en) 1979-01-30 1996-05-07 Juridical Foundation, Japanese Foundation For Cancer Research DNA and recombinant plasmid
AU538665B2 (en) 1979-10-30 1984-08-23 Juridical Foundation, Japanese Foundation For Cancer Research Human interferon dna
US4966843A (en) 1982-11-01 1990-10-30 Cetus Corporation Expression of interferon genes in Chinese hamster ovary cells
WO1986004920A1 (en) * 1985-02-13 1986-08-28 Biotechnology Research Partners, Limited Human metallothionein-ii promoter in mammalian expression system
GB2177914B (en) 1985-06-04 1989-10-25 Chugai Pharmaceutical Co Ltd A pharmaceutical composition containing human erythropoietin and a surface active agent for nasal administration for the treatment of anemia
US4954437A (en) * 1986-09-15 1990-09-04 Integrated Genetics, Inc. Cell encoding recombinant human erythropoietin
CA1294215C (en) * 1986-10-27 1992-01-14 Ze'ev Shaked Pharmaceutical compositions of recombinant beta-interferon and formulation processes
DE3712564A1 (de) 1987-04-14 1988-11-24 Bioferon Biochem Substanz Verfahren zur konstruktion einer animalen zellinie fuer die herstellung von humanem interferon-beta
DD287531A5 (de) * 1988-06-16 1991-02-28 Akademie Der Wissenschaften,De Verfahren zur herstellung von humanem wachstumshormon (sth) in tierischen zellen
DE4128319A1 (de) * 1991-08-27 1993-03-04 Bioferon Biochem Substanz Neues rekombinantes human-ifn-beta, verfahren zu dessen herstellung und dieses enthaltende pharmazeutische zubereitungen
EP0551535A1 (en) * 1992-01-13 1993-07-21 SCLAVO S.p.A. Process for the purification of recombinant human beta interferon, beta interferon thus purified, and pharmaceutical compositions which contain them

Also Published As

Publication number Publication date
AU4935896A (en) 1996-10-16
US6207146B1 (en) 2001-03-27
IL117594A0 (en) 1996-07-23
EP0815251A1 (en) 1998-01-07
GB2314332B (en) 1999-06-30
NO974367D0 (no) 1997-09-22
KR19980703275A (ko) 1998-10-15
MX9707244A (es) 1998-08-30
CA2216174A1 (en) 1996-10-03
NZ303133A (en) 1999-11-29
HK1005248A1 (en) 1998-12-31
BR9607831A (pt) 1999-11-30
CN1185180A (zh) 1998-06-17
AP9701091A0 (en) 1997-10-31
JPH11502705A (ja) 1999-03-09
GB2314332A (en) 1997-12-24
HUP9800520A3 (en) 1999-09-28
GB9506051D0 (en) 1995-05-10
AU722341B2 (en) 2000-07-27
GB9720467D0 (en) 1997-11-26
HUP9800520A2 (hu) 1998-06-29
WO1996030531A1 (en) 1996-10-03
AP730A (en) 1999-02-04
NO974367L (no) 1997-11-24

Similar Documents

Publication Publication Date Title
EP0668351B1 (en) Erythropoietin analogs
KR100361997B1 (ko) 안정한살균/투과성-증가단백질산물및그것을포함하는제약학적조성물
US4703008A (en) DNA sequences encoding erythropoietin
CA1339047C (en) Production of erythropoietin
AU595640B2 (en) Modified c-dna sequence for factor 8c
US5547933A (en) Production of erythropoietin
US6391633B1 (en) Production of erythropoietin by endogenous gene activation
US7098318B2 (en) Fusion protein having enhanced in vivo activity of erythropoietin
CA2084514A1 (en) O-glycosylated ifn-alpha
AU8978698A (en) Production of erythropoietin by endogenous gene activation
EP1453966B1 (en) Method for producing a recombinant polypeptide
AU722341B2 (en) Gene expression in mammalian cells
EP0157556A2 (en) Recombinant factor VIII-C
EP0169562A1 (en) Recominant factor VIII-R
US6555373B1 (en) Methods for identifying human cell lines useful for endogenous gene activation isolated human cell lines identified thereby, and uses thereof
US20040254351A1 (en) Hyperglycosylated polypeptides
MXPA97007244A (en) Expression of genes in mamif cells
JP2798659B2 (ja) ヒトアンチトロンビンｉｉｉ（ａｔｉｉｉ）の製造
KR100389141B1 (ko) 인간 에리스로포이에틴을 고효율로 발현하는 재조합세포주 및 이의 제조방법
RU2261276C2 (ru) Выделенная молекула днк, кодирующая эритропоэтин человека, (варианты), экспрессирующий плазмидный или вирусный днк-вектор, гликопротеид эритропоэтин (варианты) и способ его получения, фармацевтическая композиция (варианты), линия клеток млекопитающего (варианты)
CA1341607C (en) Production of erythropoietin
AU4252400A (en) Production of erythropoietin
IE83805B1 (en) Erythropoietin analogs

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees